ALNYLAM PHARMACEUTICALS, INC. Equity Securities, FV-NI, Gain (Loss)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Equity Securities, FV-NI, Gain (Loss) of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-06-30 was -$1.35M.
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-03-31 was -$956.00K, a 1325.64% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for fiscal 2025 was -$2.31M.
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for fiscal 2024 was -$3.02M.
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for fiscal 2023 was -$16.94M.
- ALNYLAM PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for fiscal 2022 was -$33.31M, a 159.81% decline from fiscal 2021.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | -$1.35M derived: sum of 3 quarters · filed 2026-07-30 | -$2.31M 10-K · filed 2026-02-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$1.35M derived: sum of 2 quarters · filed 2026-07-30 | -$2.31M 10-Q · filed 2025-10-30 | -$2.47M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$2.31M 10-Q · filed 2026-07-30 | -$2.47M derived: sum of 3 quarters · filed 2026-07-30 | -$4.04M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$956.00K 10-Q · filed 2025-05-01 | -$1.12M derived: sum of 2 quarters · filed 2026-02-12 | -$2.69M derived: sum of 3 quarters · filed 2026-02-12 | -$4.06M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | -$166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$1.73M derived: sum of 2 quarters · filed 2026-02-12 | -$3.10M derived: sum of 3 quarters · filed 2026-02-12 | -$3.02M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$2.93M derived: sum of 2 quarters · filed 2025-10-30 | -$2.86M 10-Q · filed 2025-10-30 | -$2.09M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$1.29M 10-Q · filed 2025-07-31 | -$522.00K derived: sum of 3 quarters · filed 2026-02-12 | -$17.37M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $78.00K 10-Q · filed 2025-05-01 | $845.00K derived: sum of 2 quarters · filed 2026-02-12 | -$16.00M derived: sum of 3 quarters · filed 2026-02-12 | -$14.60M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $767.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$16.08M derived: sum of 2 quarters · filed 2026-02-12 | -$14.68M derived: sum of 3 quarters · filed 2026-02-12 | -$16.94M 10-K · filed 2026-02-12 |
| 2023-09-30 | -$16.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$15.44M derived: sum of 2 quarters · filed 2024-10-31 | -$17.71M 10-Q · filed 2024-10-31 | -$10.91M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$867.00K 10-Q · filed 2024-08-01 | $5.93M derived: sum of 3 quarters · filed 2025-02-13 | -$1.92M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | -$2.27M 10-Q · filed 2024-05-02 | $4.53M derived: sum of 2 quarters · filed 2025-02-13 | -$3.32M derived: sum of 3 quarters · filed 2025-02-13 | -$4.42M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$1.05M derived: sum of 2 quarters · filed 2025-02-13 | -$2.15M derived: sum of 3 quarters · filed 2025-02-13 | -$33.31M 10-K · filed 2025-02-13 |
| 2022-09-30 | -$7.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$8.95M derived: sum of 2 quarters · filed 2023-11-02 | -$40.11M 10-Q · filed 2023-11-02 | -$45.69M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$32.26M 10-Q · filed 2023-08-03 | -$37.84M derived: sum of 3 quarters · filed 2024-02-15 | -$19.14M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$31.16M 10-Q · filed 2023-05-04 | -$36.74M derived: sum of 2 quarters · filed 2024-02-15 | -$18.05M derived: sum of 3 quarters · filed 2024-02-15 | -$22.48M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $13.11M derived: sum of 2 quarters · filed 2024-02-15 | $8.68M derived: sum of 3 quarters · filed 2024-02-15 | $55.70M 10-K · filed 2024-02-15 |
| 2021-09-30 | $18.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $14.26M derived: sum of 2 quarters · filed 2022-10-27 | $61.27M 10-Q · filed 2022-10-27 | $48.69M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$4.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | $42.58M 10-Q · filed 2022-07-28 | $30.00M derived: sum of 3 quarters · filed 2023-02-23 | $26.98M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $47.02M 10-Q · filed 2022-04-28 | $34.43M derived: sum of 2 quarters · filed 2023-02-23 | $31.41M derived: sum of 3 quarters · filed 2023-02-23 | $76.95M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$12.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$15.60M derived: sum of 2 quarters · filed 2023-02-23 | $29.93M derived: sum of 3 quarters · filed 2023-02-23 | $54.04M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$3.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $42.52M derived: sum of 2 quarters · filed 2021-10-28 | $66.63M 10-Q · filed 2021-10-28 | $77.91M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | $45.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $69.64M 10-Q · filed 2021-08-03 | $80.93M derived: sum of 3 quarters · filed 2022-02-10 | $80.91M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $24.11M 10-Q · filed 2021-04-29 | $35.40M derived: sum of 2 quarters · filed 2022-02-10 | $35.38M derived: sum of 3 quarters · filed 2022-02-10 | $35.38M derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | $11.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $11.27M derived: sum of 2 quarters · filed 2022-02-10 | $11.27M derived: sum of 3 quarters · filed 2022-02-10 | $11.29M 10-K · filed 2022-02-10 |
| 2019-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$21.00K derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $21.00K 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $21.00K 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | $3.56M 10-K · filed 2021-02-11 | |||
| 2018-06-30 | $2.04M 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | -$1.89M 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $6.98M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |